Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines

@article{Wen2011SpecificMA,
  title={Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines},
  author={Chih-Chun Wen and Huiming Chen and Swey-Shen Alex Chen and Li-Ting Huang and Wei-Ting Chang and Wenchi Wei and Li-Chen Chou and Palanisamy Arulselvan and Jin-bin Wu and Sheng-Chu Kuo and Ning Sun Yang},
  journal={Journal of Biomedical Science},
  year={2011},
  volume={18},
  pages={44 - 44}
}
BackgroundDamage-associated molecular patterns (DAMPs) are associated with immunogenic cell death and have the ability to enhance maturation and antigen presentation of dendritic cells (DCs). Specific microtubule-depolymerizing agents (MDAs) such as colchicine have been shown to confer anti-cancer activity and also trigger activation of DCs.MethodsIn this study, we evaluated the ability of three MDAs (colchicine and two 2-phenyl-4-quinolone analogues) to induce immunogenic cell death in test… Expand
Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine
TLDR
The much enhanced immunogenicity and efficacy of the current cancer vaccine formulation, that is, the use of shikonin-treated tumor cells as cell lysates for the pulse of dendritic cells in culture, may suggest a new ex vivo approach for developing individualized, d endritic cells-based anticancer vaccines. Expand
Discovery of a Novel Microtubule Targeting Agent as an Adjuvant for Cancer Immunotherapy
TLDR
A new class of tubulin depolymerizing agent is identified that acts as both an innate and an adaptive immune activating agent and that limits solid tumor growth when used concurrently with a checkpoint inhibitor. Expand
Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
TLDR
Evidence that the immune-related effects that are elicited by immunogenic cell death (ICD)-inducing therapies are strictly associated with DC engagement and activation strongly support the combination of ICD-inducing and DC-based immunotherapies. Expand
Natural compound inducers of immunogenic cell death
TLDR
The potential role of metronomic immune modulation as well as targeted delivery of ICD-inducing compounds with nanoparticles or liposomal formulations to improving the immunogenicity of I CD inducers aiming at long-term clinical benefits are highlighted. Expand
The Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy
TLDR
The various effects of tubulin inhibitors on the activities of the body’s immune system are focused on, in the hope of paving the way to develop an effective cancer therapy by combining tubulin-targeting anticancer agents and immune therapy. Expand
A novel microtubule de-stabilizing complementarity-determining region C36L1 peptide displays antitumor activity against melanoma in vitro and in vivo
TLDR
The C36 VL CDR1 peptide is a promising microtubule-interacting drug that induces tumor cell death by apoptosis and inhibits metastases of highly aggressive melanoma cells. Expand
Natural modulators of the hallmarks of immunogenic cell death.
TLDR
The identification of hallmarks of ICD is important in determining the prognostic biomarkers for new therapeutic approaches and combination treatments. Expand
Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy
Microtubule (MT)‐targeting agents are highly successful drugs as chemotherapeutic agents, and this is attributed to their ability to target MT dynamics and interfere with critical cellular functions,Expand
Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity
TLDR
Different maturation states of DCs are discussed, how they might be attained and which anticancer agents or cell death modalities (e.g., tolerogenic cell death vs. ICD) may regulate these states. Expand
Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death
TLDR
Findings support the strategy for using AC220 and an autophagy inhibitor such as TAK-165 in a combinatorial treatment to enhance the efficacy of cancer therapies. Expand
...
1
2
...

References

SHOWING 1-10 OF 69 REFERENCES
Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity.
TLDR
The data offer a description of the molecular and immunogenic characteristics of post-apoptotic tumors which can be exploited to increase the efficiency of in vivo and ex vivo TAA delivery to the DC cross-presentation pathway. Expand
Chemotherapeutic Agents Targeting the Tubulin Cytoskeleton Modify LPS-induced Cytokine Secretion by Dendritic Cells and Increase Antigen Presentation
TLDR
New immunomodulatory strategies of microtubule disrupting agents in dendritic cells are revealed, that of modifying the cytokine response to LPS and that of increasing T lymphocyte activation without induction of inflammatory cytokine secretion by d endritic cells. Expand
Discovery of novel immunostimulants by dendritic-cell-based functional screening.
TLDR
The development of a highly sensitive, unbiased functional screen to detect DC-stimulatory signals of topoisomerase I inhibitors and microtubule depolymerizing drugs and support the practical utility of the DC-based biosensor system to discover novel DC-targeted immunostimulants. Expand
Optimization of Dendritic Cell Loading With Tumor Cell Lysates for Cancer Immunotherapy
TLDR
The data suggest that ex vivo freeze-thaw of tumor cells does not effectively mimic in vivo immunogenic necrosis, and advocates careful characterization and optimization of tumor cell-derived vaccine sources for cancer immunotherapy. Expand
Calreticulin exposure dictates the immunogenicity of cancer cell death
TLDR
It is shown that anthracyclin-induced CRT translocation induces the rapid, preapoptotic translocation of calreticulin (CRT) to the cell surface and is identified as a key feature determining anticancer immune responses. Expand
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
TLDR
It is shown that even in the absence of any adjuvant, tumor cells dying in response to anthracyclins can elicit an effective antitumor immune response that suppresses the growth of inoculated tumors or leads to the regression of established neoplasia. Expand
Immunogenic cancer cell death: a key-lock paradigm.
TLDR
The concept that immunogenic death involves changes in the composition of the cell surface, as well as the release of soluble immunogenic signals that occur in a defined temporal sequence is discussed. Expand
Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
TLDR
It is speculated that human cancers that are incapable of activating the CRT exposure pathway are refractory to the immune-mediated component of anticancer therapies. Expand
Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells
TLDR
Use of PKC agonists and microtubule inhibitors to mimic TLR‐signalling, and increase the immunogenicity of CLL cells, has implications for the design of chemo‐immunotherapeutic strategies. Expand
Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells.
It has been proposed that chemotherapy enhances tumor antigen (TA)-specific immunity. The molecular form of TA from ovarian tumor that activates cellular immunity is unknown. We report hereExpand
...
1
2
3
4
5
...